Clinical trials: Triple Negative Breast Cancer (TNBC)
Triple Negative Breast Cancer, Hepatocellular Carcinoma
A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC
This study will evaluate the pharmacodynamic (PD), safety, antitumor activity, and PK of eFT508 in female subjects who have pathologically documented, radiographically measurable, metastatic or locally advanced and unresectable…
- Trial name
- NCT03318562
- Testing
- eFT508
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Effector Therapeutics
ER-Negative PR-Negative HER2-Negative Breast Cancer
Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC
Intratumoral plasmid IL-12 electroporation (IT-pIL12-EP) will be administered to approximately 10 patients with triple negative breast cancer (TNBC) with cutaneous or subcutaneous disease.
- Trial name
- TNBC (NCT02531425)
- Testing
- IT-pIL12-EP
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- OncoSec Medical Incorporated
Triple Negative Breast Cancer (TNBC)
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic…
- Trial name
- NCT06189209
- Testing
- Tenalisib
- Where
- 9 sites in India
- Volunteers
- 40 people
- Sponsor
- Rhizen Pharmaceuticals SA
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06273852
- Testing
- PBA-0405
- Where
- 4 sites in United States
- Volunteers
- 8 people
- Sponsor
- Pure Biologics S.A.
Metastatic gpNMB Over-expressing Triple Negative Breast Cancer
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC), and whose tumor cells make a…
- Trial name
- METRIC (NCT01997333)
- Testing
- CDX-011, Capecitabine
- Where
- 140 sites in United States, Australia and 7 more
- Volunteers
- 327 people
- Sponsor
- Celldex Therapeutics
Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and…
- Trial name
- NCT03184558
- Testing
- Bemcentinib; pembrolizumab
- Where
- 17 sites in United States, Norway and 2 more
- Volunteers
- 29 people
- Sponsor
- BerGenBio ASA
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Breast Cancer, Renal Cell Carcinoma
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells…
- Trial name
- MARIO-3 (NCT03961698)
- Testing
- IPI-549 (eganelisib), Atezolizumab, nab-paclitaxel
- Where
- 24 sites in United States
- Volunteers
- 91 people
- Sponsor
- Infinity Pharmaceuticals, Inc.
Triple Negative Breast Cancer
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
This is a phase 2 multicenter, double-blind, randomized, placebo-controlled, two-arm study for subjects with locally recurrent or metastatic triple negative breast cancer.
- Trial name
- BATON-BC (NCT01745367)
- Testing
- Tivozanib Hydrochloride, paclitaxel
- Where
- 54 sites in United States, Australia and 8 more
- Volunteers
- 30 people
- Sponsor
- AVEO Pharmaceuticals, Inc.
Triple Negative Breast Neoplasms
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
This is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC).
- Trial name
- NCT03838367
- Testing
- 350 mg leronlimab, 525 mg leronlimab, 700 mg leronlimab
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- CytoDyn, Inc.
Non-Small Cell Lung Cancer, Renal Cell Cancer
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult subjects with select advanced cancers.
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer
- Trial name
- NCT03454451
- Testing
- CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab
- Where
- 27 sites in United States, Australia
- Volunteers
- 117 people
- Sponsor
- Corvus Pharmaceuticals, Inc.
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
- Trial name
- TNBC (NCT02435680)
- Testing
- MCS110, carboplatin, gemcitabine
- Where
- 23 sites in United States, Australia and 10 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumor
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
This is a study to evaluate the safety and potential anti-tumor activity of an investigational drug called ARV-6723, in participants with advanced solid tumors.
- Trial name
- NCT07749586
- Testing
- ARV-6723, Pembrolizumab, SOC
- Where
- 4 sites in United States
- Volunteers
- 499 people
- Sponsor
- Arvinas Inc.
Advanced Solid Tumors
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
- Trial name
- NCT04293094
- Testing
- AMG 650
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 66 people
- Sponsor
- Volastra Therapeutics, Inc.
Triple Negative Breast Cancer
Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone for the Treatment of TNBC (TRYbeCA-2)
This is an open-label, multicenter, randomized, Phase 2/3 study in patients with locally recurrent or metastatic triple-negative breast cancer (TNBC) with no more than one prior systemic therapy for locally recurrent or…
- Trial name
- NCT03674242
- Testing
- eryaspase (L-asparaginase encapsulated in red blood cells), Gemcitabine, Carboplatin
- Where
- 16 sites in Belgium, Hungary and 1 more
- Volunteers
- 27 people
- Sponsor
- ERYtech Pharma
Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for…
- Trial name
- NCT07190469
- Testing
- PQ203
- Where
- 4 sites in United States, Canada
- Volunteers
- 80 people
- Sponsor
- ProteinQure Inc.
Triple-Negative Breast Cancer (TNBC)
A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)
This Phase Ib/IIa study is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of MR001 in patients with advanced triple-negative breast cancer (TNBC) who have progressed after prior therapy.
- Trial name
- NCT07208149
- Testing
- MR001 Bispecific Antibody for Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Shenzhen Majory Biotechnology Co., Ltd.
Breast Cancer
Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)
The primary objective of this study is to compare the efficacy of sacituzumab govitecan to the treatment of physician's choice (TPC) as measured by independently-reviewed Independent Review Committee (IRC) progression-free…
- Trial name
- ASCENT (NCT02574455)
- Testing
- Sacituzumab govitecan, Eribulin, Capecitabine
- Where
- 230 sites in United States, Belgium and 5 more
- Volunteers
- 529 people
- Sponsor
- Gilead Sciences
Advanced Solid Tumors Cancer
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics…
- Trial name
- NCT03821935
- Testing
- Livmoniplimab, Budigalimab
- Where
- 64 sites in United States, Australia and 12 more
- Volunteers
- 364 people
- Sponsor
- AbbVie
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors…
- Conditions
- Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT07020117
- Testing
- [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aktis Oncology, Inc.